Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 7/20 | 0.71 |
| ▸ | CA9 | Q16790 | 7/20 | 0.71 |
| ▸ | CA1 | P00915 | 4/20 | 0.71 |
| ▸ | CA2 | P00918 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | LGALS3 | P17931 | 4/20 | 0.49 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.49 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.46 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10061170 | 1.00 | CA12 (0.71) | CA12CA9CA1CA2ALDH1A1 | |
| SCHEMBL14178489 | 1.00 | CA12 (0.71) | CA12CA9CA1CA2ALDH1A1 | |
| SCHEMBL14384088 | 1.00 | CA12 (0.71) | CA12CA9CA1CA2ALDH1A1 | |
| SCHEMBL14384092 | 0.98 | CA12 (0.68) | CA12CA9CA1CA2ALDH1A1 | |
| SCHEMBL29556294 | 0.96 | CA12 (0.67) | CA12CA9CA1CA2ALDH1A1 | |
| SCHEMBL29492543 | 0.96 | CA12 (0.67) | CA12CA9CA1CA2ALDH1A1 | |
| SCHEMBL21067965 | 0.96 | CA12 (0.67) | CA12CA9CA1CA2ALDH1A1 | |
| SCHEMBL19418952 | 0.96 | CA12 (0.67) | CA12CA9CA1CA2ALDH1A1 | |
| SCHEMBL10061169 | 0.93 | CA12 (0.60) | CA12CA9CA1CA2ALDH1A1 | |
| SCHEMBL10026229 | 0.93 | CA12 (0.60) | CA12CA9CA1CA2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148112-B2 | Sugar chain containing 4-position halogenated galactose and application thereof | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2012-04-03 | — | — | US | disclosed |
| US-20090018327-A1 | SUGAR CHAIN CONTAINING 4-POSITION HALOGENATED GALACTOSE AND APPLICATION THEREOF | NATIONAL UNIVERSITY CORP. HOKKAIDO UNIVERSITY (JP) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018327-A1 | SUGAR CHAIN CONTAINING 4-POSITION HALOGENATED GALACTOSE AND APPLICATION THEREOF | GALK1, GALE, UGGT1 | CA12 1344/4885CA9 1217/4885CA1 1944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.